ACM Research, Inc. (ACMR) Stock Price & Analysis
ACM Research, Inc. (ACMR) closed at USD 58.09 on Thursday, October 15, 2026, down 4.96% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 61.12; the Oct 15, 2026 session ranged USD 54.72–58.31 on volume of 1,952,875 shares. Market capitalization is $4.05B, with a 52-week range of USD 28.46–127.19 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ACMR.md
Key facts (ACMR)
- Last four reported quarters (through Jun 30, 2026): revenue $1.04B, net income $150M (14.5% margin), free cash flow -$119M (SEC filings).
- Valuation: P/E 26.9x (avg 18.1x at the last 3 fiscal year-ends), EV/EBITDA 20.3x, net cash $841M.
- 3 of 80 tracked superinvestors hold ACMR (13F, Q2 2026): 1 new, 0 added, 2 reduced, 0 unchanged.
- Analysts: Buy (mean 1.80 on a 1–5 scale) (10 analysts), mean target USD 115.33 (range 75–159).
- Total return with dividends: 1Y +46.4% vs S&P 500 +18.1%; 5Y +65.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD 0.52, revenue estimate $311M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ACMR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $260M | $389M | $558M | $782M | $901M | $1.04B |
| Gross profit | $115M | $184M | $276M | $392M | $400M | — |
| Operating income | $38.7M | $59.0M | $95.8M | $151M | $109M | $138M |
| Net income | $37.8M | $39.3M | $77.3M | $104M | $94.1M | $150M |
| EPS (diluted) | $0.58 | $0.59 | $1.16 | $1.53 | $1.37 | — |
| Free cash flow | -$49.2M | -$153M | -$137M | $70.0M | -$66.6M | -$119M |
| Gross margin | 44.2% | 47.2% | 49.5% | 50.1% | 44.4% | — |
| Operating margin | 14.9% | 15.2% | 17.2% | 19.3% | 12.1% | 13.3% |
| Net margin | 14.5% | 10.1% | 13.9% | 13.2% | 10.4% | 14.5% |
| Revenue growth | +65.8% | +49.7% | +43.4% | +40.2% | +15.2% | — |
| Cash + short-term investments | $592M | $268M | $203M | $427M | $793M | — |
| Total debt | $25.4M | $21.0M | $60.7M | $150M | $214M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ACMR)
P/E 26.9x · P/S 3.9x · EV/EBITDA 20.3x · EV/Sales 3.1x · P/B 2.2x · FCF yield -2.93% · Earnings yield 3.71% · Net cash $841M · EV $3.21B
P/E at fiscal year-ends: Dec 2025 28.2x, Dec 2024 9.7x, Dec 2023 16.4x.
Superinvestors (SEC 13F-HR, Q2 2026) (ACMR)
3 of 80 tracked investors hold ACMR. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Mason Hawkins | Southeastern Asset Management | 0.92% | $17.7M | Reduced -82.2% |
| Dodge & Cox Funds | Dodge & Cox | 0.01% | $14.8M | Reduced -2.9% |
| Lee Ainslie | Maverick Capital | 0.01% | $674K | New position |
Analysts (ACMR)
Consensus Buy (mean 1.80 on a 1–5 scale), 10 analysts; mean target USD 115.33 (low 75, high 159).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-26 | Daiwa Capital | Initiated | Buy | $136 |
| 2026-06-24 | Morgan Stanley | Target raised | Overweight | $90 → $130 |
| 2026-06-18 | Roth Capital | Target raised | Buy | $100 → $125 |
Total return (dividends reinvested) (ACMR)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +46.4% | +65.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +46.6% | +10.6% |
| Volatility (annualized) | 87.1% | 76.8% |
| Max drawdown | -54.2% (Jun 2026→Oct 2026) | -82.2% (Oct 2021→Oct 2022) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 58.09 |
|---|---|
| Change | ▼ 4.96% (down) |
| Previous Close | USD 61.12 |
| Open | USD 57.32 |
| Day Range | USD 54.72 – 58.31 |
| 52-Week Range | USD 28.46 – 127.19 |
| Volume | 1,952,875 shares |
| Market Cap | $4.05B |
| Exchange | NGM |
Technical Analysis (ACMR)
Nexqual's technical model rates ACMR "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.43 (oversold) |
| vs SMA50 | Below (USD 74.92) |
| MACD | -3.19 (negative) |
Analyst Ratings (ACMR)
Wall Street analysts rate ACMR "Buy" based on 10 analysts, with a mean price target of USD 115.33 (range USD 75–159), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 115.33 |
| High Target | USD 159 |
| Low Target | USD 75 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (ACMR)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 0.52 |
| Revenue Estimate | $310.61M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.61 vs est 0.34 ▲ beat |
| 2026-03-31 | USD 0.34 vs est 0.2 ▲ beat |
| 2025-12-31 | USD 0.25 vs est 0.4 ▼ miss |
| 2025-09-30 | USD 0.36 vs est 0.53 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (ACMR)
| Total Revenue | $1.04B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +36.00% |
| Gross Margin | +43.84% |
| Operating Margin | +16.98% |
| Profit Margin | +14.48% |
| ROE | +11.63% |
| Debt / Equity | 0.15 |
| Current Ratio | 3.66 |
| Total Cash | $1.44B |
| Total Debt | $349.32M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$66.61M (-7.4% of revenue) |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (ACMR)
Nexqual rates ACM Research, Inc.'s overall financial health "Solid" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Strong — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 17% |
| Balance Sheet | Strong — $1.44B cash vs $349M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$67M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Mixed — ROE 12%, ROA 3.2% |
Ownership (ACMR)
| Insider Ownership | +3.86% |
|---|---|
| Institutional Ownership | +77.90% |
| Shares Outstanding | 64.66M |
| Float | 61.52M |
| Short % of Float | +7.49% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (ACMR)
ACM Research, Inc. is led by Hui Wang (age 64), Founder, Chairman, CEO & President, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Founder, Chairman, CEO & President | Hui Wang (age 64) |
|---|---|
| CFO, Executive VP, Secretary & Treasurer | Mark A. McKechnie (age 58) |
| Chief Financial Officer of ACM Research (Shanghai), Inc. | Yi Lu Feng (age 67) |
| Chief Executive Officer and President of ACM Research (Shanghai), Inc. | Jian Wang (age 60) |
| Vice President of Sales - North America | Jim Straus |
Major Backers & Investors (ACMR)
Notable institutional backers of ACM Research, Inc. include SmallCap World Fund Inc, Capital Group, Invesco, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SmallCap World Fund Inc | 4.53% |
| Capital Group | 3.71% |
| Invesco | 2.89% |
| Value Aligned Research Advisors, LLC | 1.63% |
| WFM ASIA (BVI) Ltd | 1.5% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 21.73% |
| Vanguard Group | 15.75% |
| State Street | 3.38% |
| Geode Capital | 2.3% |
| Dimensional Fund Advisors | 1.48% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AXTI | AXT Inc | USD 57.91 | ▼ 10.4% |
| KLIC | Kulicke and Soffa Industries, I | USD 83.05 | ▼ 6.2% |
| ACLS | Axcelis Technologies, Inc. | USD 115.11 | ▼ 7.82% |
| IPGP | IPG Photonics Corporation | USD 73.76 | ▼ 2.76% |
| AMBA | Ambarella, Inc. | USD 63.35 | ▼ 1.49% |
| VECO | Veeco Instruments Inc. | USD 45.16 | ▼ 7.5% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt